ABBVIE INC. (ABBV) News
Latest headlines that mention ABBV, newest first · each headline opens the original publisher
- Last price
- $272.42
- Day change
- +0.39%
- Next earnings
- 2026-10-30 BMO
ABBV headlines
last 30 daysA recent analyst lays out a concrete bull case, but it is not the only path to higher prices for AbbVie.
The healthcare company will release its third-quarter numbers later this month.
The addition of Genmab's Epkinly to a standard cocktail of drugs helped lymphoma patients live longer before worsening. Genmab stock rocketed. The post AbbVie Partner Flies Sky-High On News For Its $3 Billion Cancer Contender appeared first on Investor's Business Daily .
AbbVie and Medtronic are both stable blue chip dividend plays in this choppy market.
Another potential blockbuster just joined AbbVie's drug portfolio.
AbbVie boasts stronger revenue growth and free cash flow, while Bristol Myers Squibb trades at half the valuation with nearly double the profit margin.
The pharmaceutical giant still looks like a stable long-term investment.
AbbVie bets on pipeline diversification amid patent cliffs, while J&J's higher profitability masks litigation risks, a choice between growth ambition and defensive stability.
AbbVie pivots toward newer immunology drugs while Pfizer leans on acquisitions to offset pandemic decline, but their financial profiles and valuations tell starkly different stories.
Novo Nordisk trades at a steep discount on earnings and sales, while AbbVie grapples with patent cliffs and pricing pressure, but profitability tells a different story.
AbbVie leans on legacy income and portfolio transition, while Eli Lilly rides explosive growth in weight-loss drugs, but at vastly different valuations.
It would be hard for investors to replicate the company's return over the past decade.
These companies are committed to rewarding shareholders.
Also mentioned with ABBV
30dHeadlines that tag both tickers
ABBV news alerts
Get an alert by email or push when a new headline mentions ABBV.
More news
News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.